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fast track
evidence-based answer
There are 3: valacyclovir, acyclovir, and 
topical penciclovir. valacyclovir, 2 g twice 
in 1 day taken during the prodromal 
stage of herpes labialis, reduces the 
episode duration and time to healing. 
Acyclovir, 400 mg, taken 5 times a day 
for 5 days, decreases the pain duration 
and healing time to loss of crust (strength 
of recommendation [sor]: a, based 
on randomized controlled trials [rCTs]). 
Topical penciclovir 1%, acyclovir 5%, or 
docosanol 10% also decrease the duration 
of pain and healing time (sor: a, based 
on rCTs). 
 The best prophylaxis for herpes labialis 
is oral valacyclovir 500 mg daily; it reduces 
the frequency and severity of attacks (sor: 
B, based on rCT). sunscreen may be 
effective in sunlight-induced recurrence 
(sor: B, based on 2 small crossover rCTs). 
clinical commentary
let patients self-treat before breakouts
An effective management for the treatment 
of recurrent herpes labialis at the prodromal 
stage is a patient-initiated, self-treatment 
approach. In my experience, providing 
these patients with a prescription for 
valacyclovir prior to breakouts results in 
better overall outcomes. Patients are able 
to start self-treatment at the earliest signs 
of symptoms and feel more in control of 
their disease. With the lower pill burden and 
shorter treatment duration of valacyclovir, 
many patients report significantly shorter 
healing times, reduction in duration of pain, 
better compliance, and overall satisfaction. 
 This approach is particularly useful 
for patients like medical personnel and 
daycare workers, for whom outbreaks can 
pose significant adverse outcomes, such 
as loss of work days and increased risk of 
infecting others. If breakouts are frequent 
and risk of infecting others is high, consider 
daily valacyclovir as prophylaxis for these 
patients.
Tricia C. Elliott, MD, FaaFP
Kelsey-seybold Family Medicine 
residency Program, Houston, Texas
z	Evidence	summary
Herpes labialis is the most common 
presentation of herpes simplex virus 1 
(HSV-1) infection and generally repre-
sents reactivation. The disease progress-
es quickly; therefore, early treatment is 
required. 
Patient-initiated treatment can be ef-
fective. TablE	1	shows the comparison of 
oral (valacyclovir and acyclovir) and topi-
cal (penciclovir, acyclovir, and docosanol) 
antiviral agents for treatment of herpes 
labialis.1–5
Oral	treatments:		
Shortening	episodes	by	a	day
Two RCTs have shown that valacyclo-
vir (the prodrug of acyclovir, which has 
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A number  
of oral and  
topical treatments 
will reduce  
the duration of 
herpes outbreaks 
by about a day
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TablE 1
antiviral	agents	for	herpes	labialis:	a	comparison
Drug regimen   ouTcome (VS PlaceBo) 
 (or PlaceBo) n  healing Time  Pain DuraTion
Valacyclovir*  603 1.3 days ‚ (95% CI, –1.9 to –0.7) 
   (4.8 vs 6.1 days)1
  615 1.3 days ‚ (95% CI, –1.8 to –0.7) 
   (5.1 vs 6.4 days)1
acyclovir 400 mg 5 times a day 174   1.3 days ‚  
 for 5 days     (2.5 vs 3.8 days)2
Penciclovir*1%   3057 31% ‚ (Hr=1.31;   28%‚ (Hr=1.28;  
   95% CI, 1.20–1.42)3  95% CI , 1.17–1.39)3
  1573 0.7 days ‚ (4.8 vs 5.5)3  0.6 days ‚ (3.5 vs 4.1)3
acyclovir 5% 5 times a day for 4 days 689 0.5 days ‚ (4.3 vs 4.8)   0.3 days ‚ (2.9 vs 3.2 days,  
   (Hr=1.23; 95% CI, 1.06–1.44)4  Hr=1.20; 95% CI, 1.03–1.40)4
Docosanol* 10% 5 times daily 737 0.7 days ‚ (95% CI,   0.56 days ‚  (95% CI,  
(available oTC)   0.08–0.92 days)  0.125–0.69 days)  
   (4.1 vs 4.8 days)5   (2.18 vs 2.74 days)5   
* FDA approved 
CI, confidence interval; ‚, decrease; Hr, hazard ratio.
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3 to 5 times greater bioavailability) at a 
dosage of 2 g twice in 1 day significantly 
decreased the episode duration and time 
to lesion healing compared with placebo. 
In the first study (n=603), the mean epi-
sode duration was decreased by 1.1 days 
(5.0 vs 6.1 days; 95% confidence interval 
[CI], –1.6 to –0.6); in the second study 
(n=615) by 1.0 day (5.3 vs 6.3 days; 95% 
CI, –1.0 to –0.5).1 
Oral acyclovir has also been shown 
to be effective in a well-done RCT (TablE	
1). For a subgroup of patients who started 
acyclovir in the prodrome or erythema 
stage, the duration decreased (2.5 vs 3.9 
days, P=.02), but in the papular stage, it 
did not decrease significantly (2.5 vs. 3.6 
days, P=.36).2
Topical	treatments	speed	healing,	
reduce	pain
Topical penciclovir 1% cream decreas-
es the duration of lesion healing and 
pain compared with a vehicle control, 
as shown by 2 RCTs (n=3057, 1573). 
Patients initiated self-treatment every 
2 hours during waking hours for 4 days. 
In one RCT, the treatment patients lost 
classic lesions 31% faster than the place-
bo group. In another trial, healing of clas-
sical lesions was faster by 0.7 days (4.8 vs 
5.5). Benefits were achieved in both the 
early (P=.001) and later stages (P=.0055) 
of recurrence.3 
Two RCTs of topical acyclovir 5% 
cream, 5 times a day for 4 days (n=689, 
699) showed that topical acyclovir, 
compared with placebo, shortened the 
duration of an outbreak by 0.5 day (4.3 
vs 4.8) and 0.6 day (4.6 vs 5.2), respec-
tively.4 When it comes to prophylaxis, 
several studies have shown that oral 
valacyclovir and sunscreen may be ef-
fective for prophylaxis of herpes labialis 
(TablE	2).6–8
Recommendations	from	others	
The BMJ Clinical Evidence Guideline re-
iterates that oral agents (acyclovir or vala-
cyclovir) and topical agents (acyclovir or 
penciclovir) slightly reduce healing time 
and duration of pain in treating recurrent 
attack. As prophylaxis, oral acyclovir or 
sunscreen are likely to be beneficial.9
fast track
Oral valacyclovir  
is the best  
prophylaxis  
for herpes,  
reducing severity 
and frequency  
of outbreaks
C o N T I N u e D
2 g twice daily for 1 day
every 2 hours during 
waking hours for 4 days
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Drug regimen n ouTcome (VS PlaceBo)
valacyclovir (oral) 500 mg daily 98 24%‚; attack rate, 38% vs 62%; NNT=46
sunscreen various 19 Attack rate, 0% vs 71%; NNT=17
sunscreen various 19 Attack rate, 5% vs 58%; NNT=28
‚, decrease;  NNT, number needed to treat
Valacyclovir	and	sunscreen:		
Helpful	in	preventing	a	herpes	labialis	outbreak
UpToDate reports that recurrent 
herpes labialis is usually not treated 
with antivirals unless a prodromal stage 
can be identified. In these cases, oral 
acyclovir or penciclovir cream can be 
prescribed for 4 days’ duration. Chron-
ic suppressive therapy can be useful in 
immunocompetent patients with more 
than 2 episodes in 4 months, and for 
recurrences associated with systemic 
complications or those that affect job 
performance. As prophylaxis, oral acy-
clovir (200 mg 3–5 times a day) is gen-
erally used, but valacyclovir (500 mg 
once daily) is also effective.10  n
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